ITI Pharma and Healthcare Fund
The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare.
Growthvine rating: 3/5 — ranked #26 of 85 in category.
Fund basics
| Category | Equity: Sectoral |
|---|
| NAV | ₹17.63 (as of 2026-10-01) |
|---|
| AUM | ₹263 Cr |
|---|
| Expense ratio | 2.10% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Animesh Singh |
|---|
| Exit load | 0.5% for redemption within 3 months |
|---|
Performance & risk
| Sharpe ratio | 0.8 |
|---|
| Standard deviation | 16.40% |
|---|
| Max drawdown | −18.53% |
|---|
| Alpha | -3.99 |
|---|
| Beta | 0.99 |
|---|
Over 5 years, captured 92.3% of NIFTY Pharma's upside and 99.9% of its downside.
Market cap allocation
| Large cap | 36.8% |
|---|
| Mid cap | 40.3% |
|---|
| Small cap | 23.0% |
|---|
Concentration
| Top 5 holdings | 37.1% |
|---|
| Top 10 holdings | 56.9% |
|---|
| Total holdings | 37 |
|---|
Top holdings
- Sun Pharmaceutical Industries Ltd. — 12.6%
- Divis Laboratories Ltd. — 9.2%
- Apollo Hospitals Enterprises Ltd. — 5.7%
- Max Healthcare Institute Limited — 4.8%
- Torrent Pharmaceuticals Ltd. — 4.8%
- Dr. Reddys Laboratories Ltd. — 4.3%
- Cipla Ltd. — 4.2%
- Laurus Labs Limited — 4.0%
- Aurobindo Pharma Ltd. — 4.0%
- Mankind Pharma Limited — 3.3%
Top sectors
- Pharma & Biotech — 72.8%
- Healthcare — 24.2%
- Consumer Durables — 1.3%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 12.3% | Q1 (Top) | #13 of 76 |
| 2025 | −10.0% | Q4 (Bottom) | #68 of 69 |
| 2024 | 41.3% | Q1 (Top) | #7 of 58 |
| 2023 | 31.6% | Q3 | #32 of 48 |
| 2022 | −8.7% | Q4 (Bottom) | #37 of 46 |